Study guide
12.1 Vascular Anomalies & Benign Neonatal Dermatoses
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
12.1 Vascular Anomalies & Benign Neonatal Dermatoses
Key Takeaways Explain This Topic AI
The International Society for the Study of Vascular Anomalies (ISSVA) classification strictly dichotomizes vascular lesions into vascular tumours (endothelial proliferation; infantile haemangiomas are GLUT-1 positive, congenital haemangiomas are GLUT-1 negative) and vascular malformations (inborn structural dysmorphologies with normal endothelial kinetics, classified by flow velocity).
Oral propranolol (target dose 2 to 3 mg/kg/day divided into 2 daily doses taken during or immediately after feeds) is the gold-standard European consensus therapy for high-risk infantile haemangiomas, requiring screening for cardiovascular compromise and vigilant monitoring for hypoglycemia.
Large facial segmental haemangiomas (>5 cm) mandate formal evaluation for PHACE syndrome (posterior fossa malformations, haemangioma, arterial cerebrovascular anomalies, cardiac coarctation/arch defects, eye abnormalities), while lumbosacral segmental lesions require spinal MRI to rule out LUMBAR/PELVIS syndrome.
Kasabach-Merritt phenomenon (life-threatening consumptive coagulopathy with profound thrombocytopenia and hypofibrinogenemia) occurs exclusively in Kaposiform hemangioendothelioma and tufted angioma, and NEVER in classic infantile haemangioma.
Transient neonatal pustular eruptions are distinguished cytologically: erythema toxicum neonatorum presents at 24 to 72 hours with sterile eosinophilic pustules sparing palms and soles, whereas transient neonatal pustular melanosis is present at birth with sterile neutrophilic pustules frequently involving palms and soles.
Last updated: September 2026
- 12.1 Vascular Anomalies & Benign Neonatal Dermatoses
- The ISSVA Classification Framework: Tumours vs. Malformations
The diagnosis and therapeutic triage of neonatal and paediatric vascular lesions underwent a paradigm shift following the biological classification originally proposed by Mulliken and Glowacki in 1982, now codified and updated by the International Society for the Study of Vascular Anomalies (ISSVA, 2018) . Vascular anomalies are fundamentally dichotomised into two biologically distinct categories:
Vascular Tumours: Characterised by true cellular hyperplasia and endothelial proliferation . These lesions demonstrate increased endothelial cell turnover, mast cell infiltration, and lobular expansion. While typically absent or diminutive at birth, they exhibit post-natal proliferative growth followed, in many types, by variable regression.
Vascular Malformations: Characterised by abnormal vascular morphogenesis without increased endothelial cellular turnover . They represent inborn structural errors of vascular embryogenesis (dysmorphology of capillaries, veins, lymphatics, or arteries). They are always present at birth (though they may not become clinically manifest until later in childhood or adolescence) and grow commensurately with the child, never undergoing spontaneous involution.
ISSVA Biological and Clinical Distinction Matrix
Diagnostic Parameter Vascular Tumours (e.g., Infantile Haemangioma) Vascular Malformations (e.g., Port-Wine Stain, Venous)
Primary Cellular Defect Hyperplastic endothelial cell proliferation Structural dysmorphology; normal endothelial kinetics
Presence at Birth Absent or precursor macule (30–50%); manifest at 1–4 wks Present at birth (congenital, though can be subtle)
Natural History Proliferation (0–9 mo) followed by spontaneous involution Commensurate growth with child; never involutes
- Endothelial Mitoses Prominent during proliferative phase Strictly absent; flat, mature endothelium
- GLUT-1 Expression Universally Positive in Infantile Haemangioma Universally Negative
Skeletal Alterations Rare; secondary to massive mass effect Frequent (bone hypertrophy, limb discrepancy, distortion)
Haematological Risk KMP in KHE/TA; absent in Infantile Haemangioma Localized intravascular coagulopathy (LIC in venous malf.)
Infantile Haemangioma (IH)
Infantile Haemangioma (IH) is the most common benign soft-tissue tumour of childhood, occurring in 4% to 5% of Caucasian infants. Recognised risk factors include female sex (ratio 3–5:1), prematurity (especially birth weight <1500 g), multiple gestation, advanced maternal age, and chorionic villus sampling (CVS).
Life Cycle and Natural History
Precursor Lesion (Birth): Often presents as a faint, pale, vasoconstricted macule with surrounding telangiectasias, an erythematous punctate blush, or an ecchymotic/bruised area.
Proliferative Phase (0 to 9 Months): Rapid, non-linear growth during the first 3 to 6 months of life (80% of total growth occurs before 5 months of age). Superficial lesions become bright red, bosselated, and raised ("strawberry haemangioma"); deep lesions present as warm, soft, bluish subcutaneous masses; mixed lesions possess both components.
Plateau Phase (9 to 12 Months): Tumour growth stabilises, matching the growth rate of the infant.
Involution Phase (1 to 7+ Years): The lesion softens, darkens to a violaceous or dull grey hue, and flattens centripetally. The older rule of thumb that "about 10% involutes per year" overstates the timescale: most involution is complete by about 3 to 4 years of age . Post-involution residual sequelae (common, especially in thick or deep lesions) include fibrofatty tissue accumulation, anetoderma-like wrinkling, scarring, and persistent telangiectasias.
Immunohistochemical Hallmark: GLUT-1
Infantile haemangiomas demonstrate diffuse, intense, cytoplasmic immunoreactivity for erythrocyte-type glucose transporter protein 1 (GLUT-1) across all phases of development and involution. GLUT-1 is shared with placental trophoblast microvessels, Lewis Y antigen, merosin, and Fc-gamma-RII, supporting the theory that IH may originate from embolised placental tissue or early primitive endothelial progenitor cells. In contrast, vascular malformations and all congenital haemangiomas are strictly GLUT-1 negative .
Clinical Complications and Triage
Approximately 10% to 15% of IHs require urgent specialist intervention due to complications:
Ulceration: The single most common complication (15%), typically occurring during the peak proliferative phase (age 4–6 months). Predilection sites include the perineum, perioral region, and skin folds. Ulceration causes intractable pain, secondary bacterial infection, bleeding, and permanent scarring.
Visual Axis Obstruction (Amblyopia): Periocular/periorbital IH can induce permanent amblyopia via visual axis occlusion (deprivation amblyopia), direct compression of the globe causing corneal distortion (astigmatic amblyopia), or orbital infiltration leading to strabismus and proptosis.
Airway Obstruction (Subglottic Haemangioma): Segmental haemangiomas involving the mandibular or lower facial distribution ("beard distribution": lower lip, chin, mandible, anterior neck) carry a 60% risk of concurrent subglottic haemangioma , presenting as biphasic stridor, croup-like barking cough, and progressive respiratory failure between 6 and 12 weeks of age.
Anatomical and Cartilaginous Distortion: Lesions of the nasal tip ("Cyrano haemangioma"), lips, columella, and earlobes lead to destructive cartilage splaying and permanent disfigurement.
High-Output Cardiac Failure: Extensive hepatic haemangiomatosis (multiple cutaneous lesions accompanied by hepatic vascular tumours) creates profound arteriovenous or portovenous shunting, leading to hepatomegaly, congestive cardiac failure, and consumptive hypothyroidism (due to tumoral type 3 iodothyronine deiodinase activity degrading thyroid hormones).
A Critical Pitfall: Kasabach-Merritt Phenomenon (KMP)
Key distinction: Kasabach-Merritt phenomenon does not occur in infantile haemangioma . Confusing IH with KMP leads to wrong management decisions.
Kasabach-Merritt Phenomenon (KMP) is a catastrophic, consumptive coagulopathy defined by profound thrombocytopenia (platelets often <20 × 10⁹/L), hypofibrinogenemia, elevated D-dimers, and microangiopathic hemolytic anemia. It is caused by severe intralesional platelet trapping and activation within anomalous, slit-like vascular channels.
Causative Vascular Tumours: KMP occurs exclusively within Kaposiform Hemangioendothelioma (KHE) or Tufted Angioma (TA) .
Clinical Presentation: An indurated, violaceous, ecchymotic, tense, infiltrative plaque or tumor with advancing purpuric margins, characteristically located on the retroperitoneum, trunk, or proximal extremities of a neonate or young infant.
Management: First-line pharmacotherapy is the oral mTOR inhibitor Sirolimus (rapamycin) , often combined with systemic corticosteroids or vincristine. Platelet transfusions are strictly contraindicated unless life-threatening hemorrhage occurs, as transfused platelets are immediately sequestered, aggravating tumoral expansion and consumptive coagulopathy.
Syndromic Segmental Haemangiomas: PHACE and LUMBAR
Haemangiomas presenting in a segmental (plaque-like, dermatomal) distribution rather than focal/nodular carry a high risk of underlying congenital neurovascular and visceral malformations.
1. PHACE Syndrome
Large segmental infantile haemangiomas (>5 cm) of the face, scalp, or neck mandate formal multidisciplinary evaluation for PHACE Syndrome :
P (Posterior fossa brain malformations): Dandy-Walker malformation, cerebellar hypoplasia, arachnoid cysts.
H (Haemangioma): Large, segmental, plaque-like facial haemangioma (predominantly involving frontonasal, maxillary, or mandibular segments V1–V3).
A (Arterial cerebrovascular anomalies): Dysgenesis, hypoplasia, aplasia, stenosis, or aneurysmal dilatation of the internal carotid and vertebral basilar arteries, persistence of embryonic vessels (e.g., trigeminal artery).
C (Cardiac defects and aortic coarctation): Coarctation of the aorta (characteristically complex transverse arch coarctation), interrupted aortic arch, ventricular septal defects (VSD).
E (Eye abnormalities): Microphthalmia, optic nerve hypoplasia, persistent fetal vasculature, exophthalmos, iris coloboma.
Additional Feature (S): Sternal clefting or supraumbilical abdominal raphe (referred to as PHACES syndrome).
Mandatory Diagnostic Workup: MRI/MRA of the brain, head, and neck (to evaluate posterior fossa and intracranial arteries); transthoracic echocardiography with aortic arch visualization; detailed dilated ophthalmologic examination.
2. LUMBAR (PELVIS / SACRAL) Syndrome
Segmental haemangiomas localized to the lower body, lumbosacral region, perineum, or buttocks are associated with occult spinal dysraphism and urogenital abnormalities:
LUMBAR: Lower body haemangioma, Urogenital anomalies / Ulceration, Myelopathy (tethered spinal cord, lipomyelomeningocele), Bony deformities, Anorectal malformations, Renal abnormalities.
PELVIS: Perineal haemangioma, External genitalia malformations, Lipomyelomeningocele, Vesicorenal abnormalities, Imperforate anus, Skin tag.
Mandatory Diagnostic Workup: Magnetic resonance imaging (MRI) of the spine and pelvis (or spinal ultrasound if age <3–4 months before posterior vertebral arches ossify) to rule out tethered cord and intraspinal extension.
Congenital Haemangiomas: RICH, NICH, and PICH
Congenital haemangiomas are distinct vascular tumours that are fully formed at birth and do not exhibit post-natal accelerated endothelial proliferation. They are universally GLUT-1 negative .
Rapidly Involuting Congenital Haemangioma (RICH):
Solitary, violaceous, dome-shaped or plaque-like mass with prominent radial veins, peripheral pale halo, and central ulceration or depression.
Undergoes rapid, spontaneous involution starting immediately after birth, achieving near-complete regression by 12 to 14 months of age, leaving atrophic, fibrofatty tissue.
Non-Involuting Congenital Haemangioma (NICH):
Well-demarcated pink-to-violaceous plaque or exophytic tumor with coarse, overlying telangiectasias, a distinct pale border, and central warmth.
Persists indefinitely without regression, growing proportionately with the child throughout life. Treatment, if symptomatic, is surgical excision or pulsed dye laser for surface telangiectasias.
Partially Involuting Congenital Haemangioma (PICH):
Manifests initially with partial regression resembling a RICH, but involution arrests prematurely, leaving a stable lesion clinically and histologically identical to a NICH.
Vascular Malformations: Classification by Flow Velocity
Vascular malformations arise from defective embryologic morphogenesis and are subclassified based on fluid hemodynamics:
1. Slow-Flow Malformations
Capillary Malformation (Port-Wine Stain / Naevus Flammeus):
Flat, sharply demarcated, pink-red macular patch present at birth that darkens to a deep purple, thickens, and develops vascular nodules (cobblestoning) in adulthood.
Caused by somatic mosaic activating mutations in GNAQ (p.Arg183Gln) or GNA11 .
Sturge-Weber Syndrome (Encephalotrigeminal Angiomatosis): High risk when the port-wine stain involves the V1 (ophthalmic) division of the trigeminal nerve (forehead and upper eyelid). Manifests with ipsilateral leptomeningeal angiomatosis (causing intractable epilepsy, progressive ischemic stroke-like episodes, developmental delay, and cortical tram-track calcification on CT/MRI) and congenital or juvenile glaucoma (elevated episcleral venous pressure or trabecular dysgenesis). Treatment of skin: Pulsed dye laser (PDL, 595 nm).
Klippel-Trenaunay Syndrome (KTS): Low-flow combined capillary-venous-lymphatic malformation associated with soft tissue and bony hypertrophy of an extremity (most commonly lower extremity) and anomalous lateral embryonic veins (vein of Servelle). Caused by somatic mosaic mutations in PIK3CA (part of the PIK3CA-Related Overgrowth Spectrum / PROS).
Venous Malformation (VM):
Soft, compressible, non-pulsatile bluish subcutaneous nodules or masses that swell with dependency or Valsalva manoeuvre. Pain arises from thrombosis leading to round, calcified phleboliths visible on plain radiography or MRI.
Driven by somatic mutations in the endothelial tyrosine kinase receptor TEK (TIE2) or PIK3CA .
Blue Rubber Bleb Nevus Syndrome (Bean Syndrome): Multiple tender, cutaneous "rubber bleb" venous malformations associated with extensive gastrointestinal venous malformations, resulting in chronic iron-deficiency anemia from occult GI hemorrhage.
Lymphatic Malformation (LM):
Subdivided into macrocystic (>2 cm cysts; cystic hygroma of the neck/axilla) and microcystic (clusters of translucent vesicles resembling "frog spawn", frequently complicated by intralesional bleeding and lymphorrhea).
2. Fast-Flow Malformations
Arteriovenous Malformation (AVM) and Arteriovenous Fistula (AVF):
Direct communication between arteries and veins bypassing the capillary bed. Present clinically as warm, pink-red, pulsatile masses with a palpable thrill and continuous audible bruit.
Classified by the Schobinger clinical staging system : Stage I (quiescence: pink warm patch resembling PWS), Stage II (expansion: tortuosity, thrill, bruit), Stage III (destruction: ulceration, bleeding, pain, necrosis), Stage IV (decompensation: high-output congestive heart failure).
Driven by somatic mutations in MAP2K1 or germline RASA1 / EPHB4 (capillary malformation-AVM syndrome).
European Consensus Management of Infantile Haemangioma
The discovery in 2008 by Léauté-Labrèze and colleagues that beta-adrenergic antagonists induce rapid involution revolutionized IH therapeutics, displacing systemic corticosteroids as first-line treatment.
Mechanism of Action of Beta-Blockers
Propranolol acts via three complementary pathways:
Early Phase (Hours to Days): Vasoconstriction secondary to local release of nitric oxide reduction, causing palpable softening and lightening of the lesion.
Intermediate Phase (Weeks): Downregulation of pro-angiogenic growth factors including VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) via the MAPK/ERK signaling pathway.
Late Phase (Months): Induction of endothelial cell apoptosis and recruitment of tissue inhibitors of metalloproteinases, accelerating fibrofatty replacement.
European Treatment Guidelines and Protocol
First-Line Systemic Therapy: Oral Propranolol Hydrochloride (approved by the EMA as an oral paediatric formulation at 3.75 mg/mL).
Indications for Treatment:
Life-threatening complications (subglottic/tracheal obstruction, high-output cardiac failure).
Functional impairment (periocular IH impeding vision, external auditory canal occlusion, lip/feeding compromise).
Active or impending ulceration with severe pain.
High risk of permanent disfigurement (nasal tip, lip columella, large facial segmental lesions).
Therapeutic Dosing Schedule:
Initiation: Start at 1 mg/kg/day divided into two doses.
Titration: Increase after 1 to 2 weeks to the target maintenance dose of 2 to 3 mg/kg/day (standard consensus maintenance: 2.0 to 3.0 mg/kg/day administered in two divided doses spaced at least 9 hours apart).
Administration Rule: Must be administered during or immediately following a milk feed .
Contraindications: Sinus bradycardia, second- or third-degree atrioventricular (AV) block, cardiogenic shock, hypotension, active bronchospasm / bronchial hyperreactivity (asthma), hypersensitivity to propranolol, and neonates with corrected gestational age <5 weeks.
Mandatory Pre-Treatment Screening: Clinical cardiovascular examination (heart rate, blood pressure, cardiac auscultation for murmurs). Routine electrocardiogram (ECG) is indicated only if baseline heart rate is below age-adjusted normal, if an arrhythmia is auscultated, or if there is a personal/family history of congenital heart disease or long QT syndrome. In patients with facial segmental IH, PHACE syndrome must be ruled out with brain/neck MRA and echocardiogram prior to starting propranolol , as rapid blood pressure drop can precipitate acute cerebral infarction in the presence of severe arch coarctation or intracranial arterial hypoplasia.
Critical Adverse Effects & Safety Management:
Hypoglycemia: Propranolol blocks glycogenolysis, gluconeogenesis, and masks adrenergic hypoglycemic warning symptoms (tachycardia, tremor, agitation; diaphoresis is preserved). To prevent fatal hypoglycemia, propranolol must be withheld during acute intercurrent illnesses with poor feeding, vomiting, or diarrhea .
Bradycardia and Hypotension: Assessed during dose escalations; typically asymptomatic and transient.
Bronchospasm / Wheezing: Beta-2 receptor antagonism induces bronchoconstriction; withhold during acute viral bronchiolitis.
Sleep Disturbance: Night terrors, vivid dreams, somnolence, cold peripheral extremities.
Treatment Duration: Maintained continuously until 12 to 15 months of age , spanning the natural proliferative phase. Tapering over 2 to 4 weeks prevents rebound regrowth (rebound occurs in 10–15% of cases, responding to re-initiation).
Topical Beta-Blockers: Topical Timolol Maleate 0.5% gel-forming solution (1–2 drops twice daily) is reserved for small, superficial, thin (<1–2 mm), non-problematic haemangiomas where systemic absorption is negligible.
Benign Transient Neonatal Pustular Dermatoses
Neonatal pustular and vesicular eruptions represent common, anxiety-provoking presentations. A critical clinical competency is distinguishing benign, self-limiting sterile conditions from life-threatening neonatal infections (e.g., Neonatal Herpes Simplex Virus, Congenital Candidiasis, Staphylococcal Scalded Skin Syndrome, Listeriosis).
1. Erythema Toxicum Neonatorum (ETN)
Incidence & Onset: The most common pustular eruption, affecting 40% to 50% of full-term neonates. Arises typically between 24 and 72 hours of life ; rare in premature infants <35 weeks.
Morphology & Distribution: Splotchy, erythematous macules (2–3 cm) with central 1–2 mm pale-yellow to white firm papules or pustules, producing a classic "flea-bite" appearance. Distributed over the chest, back, face, and proximal extremities. Strictly spares the palms and soles .
Tzanck / Cytologic Smear: Wright-Giemsa or Gram stain of the pustule contents reveals a dense sheet of intact eosinophils (>90%) ; Gram stain demonstrates no bacteria.
Pathogenesis & Prognosis: Sterile inflammatory response around the hair follicle infundibulum (innate immune response to initial microbial commensal colonization). Completely benign; resolves spontaneously within 7 to 14 days without treatment.
2. Transient Neonatal Pustular Melanosis (TNPM)
Incidence & Onset: Present at birth in up to 5% of Black neonates and 0.5% of Caucasian neonates.
Triphasic Evolution:
Phase 1: Fragile, 2–4 mm superficial pustules or vesicopustules lacking surrounding erythema, present at delivery.
Phase 2: Pustules rupture within 24–48 hours, leaving a delicate collarette of fine white scale surrounding a hyperpigmented macule.
Phase 3: Non-inflammatory, pinpoint hyperpigmented brown macules that persist for several weeks to months before spontaneous resolution.
Distribution: Chin, neck, forehead, lower back, and frequently involves the palms and soles (unlike ETN).
Tzanck / Cytologic Smear: Aspiration of intact pustules reveals a predominance of neutrophils alongside cellular debris and rare eosinophils; sterile.
3. Miliaria (Eccrine Duct Occlusion)
Caused by retention of eccrine sweat due to occlusion of the sweat duct under conditions of warmth and high humidity:
Miliaria Crystallina (Sudamina): Occlusion at the stratum corneum . Fragile, clear, non-inflammatory, superficial vesicles resembling "dewdrops" on normal skin without erythema. Rupture easily.
Miliaria Rubra ("Prickly Heat"): Occlusion within the stratum spinosum (intraepidermal) . Intensely pruritic, erythematous papules and tiny vesicles on an erythematous base located in intertriginous folds, neck, and trunk.
Miliaria Profunda: Occlusion at the dermo-epidermal junction . Rare in neonates; firm, pale, flesh-colored non-inflammatory papules.
4. Neonatal Cephalic Pustulosis (Neonatal Malassezia Pustulosis)
Onset & Morphology: Manifests at 2 to 4 weeks of age (not present at birth). Multiple tiny inflammatory papules and pustules scattered over the cheeks, forehead, chin, eyelids, and scalp.
Etiology: Inflammatory host reaction to colonization with lipophilic yeasts of the genus Malassezia ( M. sympodialis , M. furfur ), stimulated by maternal androgens on infant sebaceous glands.
Critical Distinction from True Infantile Acne: Neonatal cephalic pustulosis exhibits complete absence of comedones (no blackheads or whiteheads). In contrast, true Infantile Acne arises later (3 to 6 months), features open and closed comedones, inflammatory cysts, risks scarring, and requires endocrine evaluation if accompanied by virilisation or hirsutism.
Management: Self-limiting, but rapidly resolves with topical 2% ketoconazole cream twice daily for 7 to 10 days.
Differential Diagnosis Matrix: Neonatal Pustular & Vesicular Dermatoses
Condition Typical Onset Primary Morphology Palm & Sole Involvement Cytologic Smear (Tzanck/Gram) First-Line Management
Erythema Toxicum Neonatorum (ETN) 24–72 hours of life Blotchy erythema with central 1–2 mm yellow pustules ("flea-bite") Spared Dense Eosinophils (>90%) ; Sterile Reassurance; resolves in 1–2 weeks
Transient Neonatal Pustular Melanosis (TNPM) At birth Superficial pustules -> collarettes of scale -> pigmented macules Frequently involved Neutrophils ; Sterile Reassurance; macules fade over months
Miliaria Crystallina Days to weeks Clear, fragile 1 mm superficial vesicles ("dewdrops"); no erythema Spared Amorphous keratin debris Cooling; avoid over-bundling
Miliaria Rubra Days to weeks Punctate erythematous papules/vesicles in flexures; pruritic Spared Mild lymphocytic infiltrate Cool environment, light clothing
Neonatal Cephalic Pustulosis 2–4 weeks Erythematous papulopustules on face/scalp; NO comedones Spared Malassezia budding yeasts / hyphae Topical ketoconazole 2% cream
Infantile Acne 3–6 months Papules, pustules, cysts with Comedones present Spared Neutrophils; Cutibacterium acnes Topical retinoids/benzoyl peroxide
Congenital Cutaneous Candidiasis At birth to 48 hrs Diffuse bright erythema with satellite pustules; burn-like Involved Pseudohyphae & budding spores Topical / systemic nystatin or fluconazole
Neonatal Herpes Simplex (HSV) Day 5 to day 21 Grouped vesicles on erythematous base; erosions; scalp/face Variable Multinucleated giant cells (Tzanck); HSV PCR Intravenous Aciclovir (60 mg/kg/day)